Viridian Therapeutics (STU:1S1) Construction In Progress: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S1 Viridian Therapeutics Inc STU:1S1
52 GF Score
Price €19.90
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Construction In Progress?

Viridian Therapeutics STU:1S1 -1.49% 52 Construction In Progress is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:1S1 with a GF Score™ of 52/100. The stock has 5 warning signs investors should review.

Viridian Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Construction In Progress Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:1S1
52GF Score
Viridian Therapeutics Inc STU:1S1
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Viridian Therapeutics (STU:1S1) has a Construction In Progress of €0.00 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Viridian Therapeutics and its competitors.
Is Viridian Therapeutics' Construction In Progress too high?
Viridian Therapeutics' current Construction In Progress is €0.00 Mil. Overall, Viridian Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Construction In Progress compare to BHVN and AGIO?
Viridian Therapeutics' Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (STU:1S1) has a current Construction In Progress of €0.00 Mil. The current Construction In Progress is €0.00 Mil. Viridian Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current Construction In Progress is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA0K1R:UK
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
52GF Score

Get the complete analysis for STU:1S1

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.90
Price